End-of-day quote
Other stock markets
|
||
- USD | - |
|
08/07 | CASI Pharmaceuticals Names Daniel Lang CFO | MT |
08/07 | CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 43 | 100.0 % | 34 | 100.0 % | -21.41% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 43 | 100.0 % | 34 | 100.0 % | -21.41% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Wei Zhang
PSD | President | 64 | 01/18/01 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 01/17/01 |
Chief Tech/Sci/R&D Officer | 65 | 01/17/01 | |
Wei Gao
LAW | General Counsel | 42 | 01/23/01 |
Kun Qian
AUD | Comptroller/Controller/Auditor | 42 | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Yue Wu
BRD | Director/Board Member | 62 | 01/13/01 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 21/23/21 |
Thomas Folinsbee
BRD | Director/Board Member | 57 | 21/23/21 |
Xue Bo Zeng
BRD | Director/Board Member | 39 | 21/23/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,813,327 | 8,607,899 ( 62.32 %) | 411,952 ( 2.982 %) | 62.32 % |
Company contact information
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road
100025, Beijing
+
http://www.casipharmaceuticals.com![address ENTREMED](https://cdn.zonebourse.com/static/address/9182.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+55.35% | 82TCr | |
+32.45% | 60TCr | |
-0.10% | 38TCr | |
+15.47% | 32TCr | |
+13.10% | 31TCr | |
+16.29% | 25TCr | |
+15.15% | 23TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |
- Stock Market
- Equities
- CASI Stock
- Stock
- Company ENTREMED